Category: 8. Health

  • The World Is On the Verge of Wiping Out Polio — So Why Did Germany Cut Funding Now?

    The World Is On the Verge of Wiping Out Polio — So Why Did Germany Cut Funding Now?

    The world is close to wiping out polio, and that in itself is close to miraculous. Of the thousands of diseases that afflict humans, only one, smallpox, has ever been eradicated before.

    But despite tremendous progress, polio isn’t going down without a fight. Budget cuts, vaccination gaps, and difficulties reaching hard-to-access communities keep pushing the finish line further back. As cases creep upward, virus strains have re-emerged in countries that were long ago declared polio free — including Germany.

    What makes that even more worrying? Germany is one of the latest countries to cut down its international aid budget, planning to trim €17 million from polio vaccination efforts alone in 2025 and 2026. These financial shortfalls could end up accelerating polio’s spread, ushering in a future where resurgences become the norm.

    We spoke with the World Health Organization (WHO) to find out exactly how Germany’s budget cuts could spell future trouble for all of global health.

    But First — What Exactly Is Polio? 

    Poliomyelitis, or polio, is a highly infectious virus that spreads mainly through contaminated water and food, mostly striking children under five. It usually settles in the gut but can eventually attack the central nervous system. Its symptoms are brutal, ranging from fever, headaches, and vomiting, to irreversible paralysis in about 1 of every 200 infections. In the worst cases it can even paralyze breathing muscles, causing suffocation. In fact, a horrific outbreak of polio in Copenhagen in 1952 prompted doctors to create the first ‘iron lung’ — a precursor to today’s hospital intensive care units (ICUs). 

    Before vaccines entered the picture in the 1960s, there were more than 600,000 cases recorded worldwide each year. There’s still no cure — but it can be prevented, which is partially why global health advocates set their sights on the goal of eradicating it entirely.

    As Dr. Shahin Huseynov, Regional Advisor at the WHO Regional Office for Europe, explained, “The chance of success in eradicating polio is unique.” While the virus is incredibly contagious, unlike coronaviruses or monkeypox, it can’t infect animals — eliminating a loop of cross-contamination and putting victory within reach.

    How the World United to Fight Back

    In 1988, the Global Polio Eradication Initiative (GPEI) launched as a partnership between major global health heavy-hitters like WHO, UNICEF, the US Center for Disease Control, the Gates Foundation, Rotary International, Gavi, and others. With two powerful vaccines introduced — the cheap, accessible oral polio vaccine (OPV) delivered by drops, and the highly effective injectable inactivated polio vaccine (IPV) — global immunization campaigns began, driving infections down by 99%.

    In the 1980s, wild poliovirus paralyzed about 1,000 children daily. But by 2021, cases had dwindled to single digits. “To date, 20 million cases of paralysis have been prevented — one of humanity’s greatest achievements in global health. The eradication of the second disease in history after smallpox seems within reach,” said Dr. Huseynov.

    In wealthy nations with strong healthcare systems and widespread vaccination resources, fears of polio have largely become a relic of history. Germany, for instance, saw its last case of wild polio decades ago in 1990.

    So How Has Polio Stuck Around? 

    Total eradication requires closing every elusive immunization gap worldwide at once — a daunting task. At-risk communities face a litany of obstacles including faltering funding, conflict, weak infrastructure, misinformation, and slipping vaccination rates, leaving openings for the virus to proliferate.

    Still, GPEI has scored some major triumphs. India was declared polio-free in 2014, as well as the entire African continent in 2020. And as Dr. Huseynov emphasized: “The polio program is more than just a vaccination program. It strengthens local health systems and achieves success even in crisis areas.”

    “GPEI health workers have provided the infrastructure for COVID-19 vaccination campaigns, fought Ebola outbreaks, taken malaria prevention measures, and continuously improved disease surveillance. Even in the recent conflict in the Gaza Strip, a humanitarian pause allowed children to be vaccinated — a measure that was only possible thanks to the existing infrastructure of the polio program.”

    Yet challenges remain. Wild polio is still endemic in Afghanistan and Pakistan, where political instability, misinformation, and rural inaccessibility fuel setbacks. COVID-19 also paid polio a huge favor by disrupting global childhood immunization campaigns. “If the international community fails now, the virus will return. Models predict 200,000 children will be paralyzed each year if this happens, including in Europe,” added Dr. Huseynov.

    If that happens, decades of effort and billions of dollars will have been effectively wasted. 

    How Polio Bounces Back 

    Another chilling complication? Variant, or vaccine-derived poliovirus (VDPV). Though rare, this emerges when weakened strains from the OPV are able to spread and end up mutating and strengthening, threatening unvaccinated communities and immunocompromised individuals. In 2024, variants of poliovirus were found in 38 countries worldwide, including Palestine and Yemen. Since 2022, VDPV has been found everywhere from Jerusalem, London, Finland, Spain, Poland, and New York City — where an unvaccinated young man subsequently developed polio, leaving him paralyzed.

    And as Dr. Huseynov warned, Germany has also found VDPV in wastewater across major cities since late 2024, including Munich, Berlin, Bonn, Cologne, Hamburg, Dresden, Düsseldorf, Stuttgart, and Mainz. “This is an alarming signal. It highlights the fact that even in Germany and other high-income countries of Europe, there is a risk of infection for people who are not adequately protected against the virus. Combating the disease at its source is therefore crucial also for the protection of public health in Germany.”

    The Cost of Cutting Budgets

    Currently, polio eradication campaigns are like a game of whack-a-mole — but to finish the job, every outbreak everywhere must be stopped, all at once. That requires steady international coordination, along with harmonious synchronization of vaccine supply, access, political will, public demand, and crucially, funding to back it all up.

    GPEI relies primarily on governments and NGOs for its financial support. Dr. Huseynov explained, “Significant reductions to the GPEI’s budget mean certain activities, like disease surveillance and critical immunity building, may not be able to continue everywhere… Not least, the withdrawal of the US from key areas of global health financing once again highlights that multilateral solutions are more important than ever.”

    Germany is GPEI’s historic third-largest donor. Since its founding, it has donated €854 million — proportionally, this means Germany has helped GPEI immunize 123 million children and avert 824,000 cases of paralysis since 1988. At the 2022 World Health Summit in Berlin, it pledged €72 million over 2022–2026. But now it’s looking to cut €17 million over the next two years — nearly half its commitment for that time frame. “These cuts not only send the wrong signal to other countries, but also jeopardize the successes achieved by GPEI.” Based on previous calculations, this cut could result in 2.6 million fewer vaccinated children around 17,700 children at risk of lifelong paralysis. 

    Dr. Huseynov also explained that Germany’s funding isn’t earmarked for any specific region or program, making its contribution extra impactful as it gives GPEI flexibility to direct resources where they’re needed most. With less to work with, campaigns could face delays and difficult trade-offs. And left unchecked, viruses will inevitably spill across borders, creating the perfect conditions for a global health crisis to spiral. 

    New Donors on the Horizon?

    GPEI’s endgame strategy requires $6.9 billion through 2029. While some wealthy nations are stepping back, others are stepping up: Pakistan is funding more of its own efforts through subsidized loans, Saudi Arabia pledged $500 million earlier this year, and the UAE funded a large-scale campaign after last year’s outbreak in Gaza.

    But fragile states facing outbreaks today like Afghanistan, Somalia, and Yemen still lack the resources to do the same. Without sustained commitments from long-standing donors like Germany, eradication will keep slipping out of reach — giving the virus time to evolve and spread as the world stumbles at the finish line.

    Near-Victory Isn’t Enough

    Eradicating polio for all is still possible — but viruses thrive amid negligence. Global health depends not just on scientific breakthroughs, but also simple human choices. Whether world leaders use the tools we have at hand, or fail to, determines health outcomes for all.

    Many in Germany and across the Global North have never experienced polio, making it easy to dismiss its gravity. But the stakes are generational. As Dr. Huseynov emphasized, “With prioritization of health security, Germany has a unique chance to regain a leadership role in the fight against polio and in safeguarding the health of Europe.”

    The finish line is in sight. Now is the time to double down, not pull back. Memories may be short — but the consequences of failing to act could last lifetimes.


    Continue Reading

  • An animal sedative keeps turning up in opioid deaths – what you need to know about medetomidine

    An animal sedative keeps turning up in opioid deaths – what you need to know about medetomidine

    A dangerous new drug adulterant is spreading through America’s illicit opioid supply, and it’s making overdoses significantly harder to reverse. Medetomidine, a veterinary sedative normally used to sedate pets, is increasingly being mixed with heroin and fentanyl, creating a cocktail that experts warn could be far deadlier than previous street drug combinations.

    Known as “flysky” on the streets, this animal tranquilliser has already been linked to at least two overdose deaths in Pennsylvania and represents a troubling evolution in the continuing opioid crisis. Unlike traditional opioid overdoses, those involving medetomidine can’t be effectively treated with naloxone, the medication paramedics use to reverse overdoses.

    The emergence of medetomidine mirrors the earlier spread of xylazine, another veterinary sedative that earned the nickname “zombie drug” for its ability to cause severe, treatment-resistant skin wounds. The earliest confirmed detection of medetomidine as a street drug adulterant occurred in Maryland, where it was found in a synthetic opioid mixture probably containing fentanyl.

    From there, the drug spread rapidly. Traces appeared across multiple US states and into Canada, and by early 2024, medetomidine was linked to overdose clusters in Philadelphia and other locations, following the same geographical pattern that xylazine had taken years earlier.

    Unfortunately, opioid-overdose reversal drugs don’t work against veterinary tranquillisers.
    rblfmr/Shutterstock.com

    What makes medetomidine particularly concerning is its extraordinary potency. Medetomidine is an alpha-2 adrenergic receptor agonist – a type of drug that affects the nervous system. While approved only for veterinary use in the UK to sedate animals and provide pain relief for pets, experts estimate it may be 200 to 300 times more potent than xylazine when used as a drug adulterant.

    This extreme potency means that even tiny amounts can have devastating effects. Users experiencing medetomidine-laced drug overdoses typically display extreme drowsiness, muscle twitching, dangerously low heart rate and blood pressure, and laboured breathing.

    Chicago cases from 2024 revealed additional concerning symptoms: extremely high blood pressure, severe confusion and critically low blood oxygen levels – often dropping below 90%, a threshold that can cause organ damage.

    Perhaps most alarming is medetomidine’s resistance to naloxone, the opioid overdose-reversal drug that has saved countless lives. While naloxone can counteract heroin and fentanyl by blocking opioid receptors in the brain, medetomidine affects the body through entirely different pathways. This means there is no approved antidote for medetomidine poisoning, leaving healthcare professionals with limited options when treating overdoses involving this adulterant.

    The withdrawal process is equally tricky. Philadelphia health officials report that people withdrawing from medetomidine-laced drugs experience dangerous spikes in blood pressure and heart rate – symptoms severe enough to trigger a heart attack in some cases. Users also endure uncontrollable nausea and vomiting, intense anxiety, restlessness and violent shaking.

    Understanding why dealers add these veterinary drugs to street opioids requires examining the economics of the illicit drug trade. According to a 2022 DEA report, a kilogram of xylazine powder can be bought from Chinese suppliers for as little as U$6.00 (£4.44). This rock-bottom pricing allows drug traffickers to increase their profit margins significantly while making weak or diluted opioid batches feel more potent to users.

    These sedatives also serve as effective cutting agents (substances used to add bulk and weight to drugs without requiring expensive active ingredients). For dealers, it’s a win-win. They can stretch their supply while creating a product that feels stronger and lasts longer than pure opioids alone.

    Managing new drug adulterants like medetomidine presents unique difficulties for both medical professionals and law enforcement. The drugs make intoxication and withdrawal symptoms more severe and complicated, while also making it harder to identify which specific substance is causing particular symptoms in a patient.

    Medetomidine compounds these problems because it’s rapidly metabolised by the body, making it difficult to track the timing and duration of its effects. Additionally, these veterinary sedatives are not included in routine drug screenings or toxicology tests, meaning their presence often goes undetected by medical professionals and law enforcement, despite their potentially lethal effects.

    UK response

    While no cases of acute medetomidine toxicity have been published in the UK, the country has already experienced problems with xylazine, a similar veterinary sedative.

    British health authorities have detected xylazine in 35 cases through toxicology tests and drug seizures. Of 16 people found to have xylazine in their systems, 11 cases proved fatal – deaths that occurred primarily during May 2022 and August 2023.

    In response to the growing threat, the government has taken decisive action. Over 20 dangerous substances have been banned as part of efforts to combat synthetic drugs and improve public safety.

    Xylazine is now controlled as a class C substance, carrying penalties of up to two years in prison for possession and up to 14 years for production and supply.

    The government is also working to better equip police, healthcare workers and Border Force agents to tackle this evolving threat through improved training and detection capabilities.

    The case of medetomidine highlights a disturbing reality about modern drug policy: the illicit drug supply continues to change in unpredictable and dangerous ways. Neither medetomidine nor xylazine was developed for human consumption, and there are no human studies examining their drug interactions, lethal doses or safe reversal protocols.

    As these veterinary sedatives become more common in street drugs, the challenge for healthcare professionals continues to grow. Traditional overdose response protocols, built around reversing opioid effects with naloxone, become inadequate when faced with multi-drug combinations that affect the body through completely different mechanisms.




    Read more:
    ‘There has never been a more dangerous time to take drugs’: the rising global threat of nitazenes and synthetic opioids


    For users, families and communities already devastated by the opioid crisis, the emergence of medetomidine represents yet another layer of risk in an already dangerous landscape.

    As the drug supply becomes increasingly unpredictable, the need for comprehensive approaches to drug policy – encompassing everything from harm reduction to treatment access to law enforcement – becomes ever more urgent.

    Continue Reading

  • Continue Reading

  • WHO adds weight-loss, diabetes drugs to essential medicines list | World Health Organization News

    WHO adds weight-loss, diabetes drugs to essential medicines list | World Health Organization News

    UN agency urges production of affordable generics for GLP-1 drugs to treat obesity and diabetes in developing countries.

    The World Health Organization (WHO) has added a new set of drugs for obesity and diabetes to its essential medicines list, alongside treatments for cancer and cystic fibrosis.

    Cheap generic versions of the glucagon-like peptide-1 (GLP-1) drugs should also be made available for people in developing countries, the United Nations agency said in a statement on Friday.

    Recommended Stories

    list of 3 itemsend of list

    The list, consisting of 523 medicines for adults and 374 for children, is a catalogue of the drugs the WHO believes should be available in all functioning health systems.

    “The new editions of essential medicines lists mark a significant step toward expanding access to new medicines with proven clinical benefits and with high potential for global public health impact,” said Yukiko Nakatani, WHO’s assistant director-general for Health Systems, Access and Data.

    The expert committee added the active ingredients in Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro to the list, to treat type 2 diabetes in conjunction with established cardiovascular disease, chronic kidney disease or obesity.

    The medicines were initially developed for diabetes, and have become wildly popular as weight-loss drugs, too, under different brand names. But the WHO stopped short of adding them to treat obesity alone, as it also did in 2023.

    The committee said this decision provided clear guidance on which patients would most benefit from the therapies.

    “High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines,” the WHO statement added, saying that encouraging generic drugmakers to produce the product would also help when patents begin to expire on the drugs next year.

    Other additions

    According to the WHO, more than 800 million people around the world were living with diabetes in 2022, while more than one billion people are affected by obesity.

    Earlier this year, the organisation announced plans to recommend the use of medications for obesity, which is separate from their inclusion on the essential medicines list.

    WHO data shows that, in 2021, more than 3.7 million people died from conditions linked to being overweight or obese – a number that exceeds the combined deaths from malaria, tuberculosis and HIV.

    The list also includes Vertex Pharmaceuticals’ combination therapy for cystic fibrosis, Trikafta or Kaftrio. Activists have criticised its high price and lack of accessibility for years.

    WHO’s list also includes Merck’s top-selling cancer immunotherapy drug, Keytruda, for the treatment of cervical cancers, colorectal cancers, and non-small cell lung cancers that have spread, or metastasised. The agency also recommended strategies to increase access to this drug.

    The WHO further added rapid-acting insulin analogues, also made by Novo Nordisk and Eli Lilly, among others, to the list for treating type 1, type 2 and gestational diabetes.


    Continue Reading

  • Viral: Chinese café that sells coffee at -86 degrees Celsius has netizens in shock

    Viral: Chinese café that sells coffee at -86 degrees Celsius has netizens in shock

    Image credits: Instagram/shufofood

    Hot and cold coffee have been fan favourites for decades. But have you ever heard of freezing cold coffee? Not yet? Well, it’s time.Recently, a Chinese digital creator and food vlogger Shufosho shared a video on Instagram, sharing with viewers a glimpse at an extraordinary coffee drink. “I got this coffee in China, served in a -86 degree glass. It was created as a way to make iced lattes without ice,” he said in the clip.

    How is the freezing cold coffee made?

    How is the freezing cold coffee made?

    Image credits: Instagram/ shufofood

    The staff takes a frozen cup from a -86 degree Celsius freezer, pours milk into the frosty cup and then tops it up with rich, aromatic coffee. Since the cup consists of frost, it doesn’t need extra ice.“Because melting ice dilutes the flavour, the owner recommended drinking it in big gulps without stirring, immediately after it’s made. This way, the hot espresso and super-cold milk create a contrasting taste – kind of like ice cream on a warm apple pie,” revealed the vlogger.The name of the café was Luna Café at 24 Fanghua Street, Chengdu, China. The video about their unique coffee service has received 120K likes and numerous comments from curious netizens.

    Netizens react to the freezing coffee

    People on the internet have been amazed by the extraordinary recipe shown in the reel. Many took to the comments to share their reactions, wanting to try the coffee.“Someone in the USA recreate this so I can have it for 100 dollars yay,” wrote one.Others were wondering about the science associated with the recipe, writing, “I’m surprised that pouring boiling hot water into these does not crack them” and “Wouldn’t the jar explode?”“Wouldn’t your fingers getting freezed touching the cold cup?” pondered another.“Don’t forget to peel off ur lips afterwards 😂,” quipped another.


    Continue Reading

  • Fine Particulate Matter Exposure Tied to Lewy Body Dementia

    Fine Particulate Matter Exposure Tied to Lewy Body Dementia

    A team of researchers at Johns Hopkins Medicine say they have revealed a possible molecular connection between air pollution and an increased risk of developing Lewy body dementia.

    The findings add to a growing body of evidence indicating how environmental factors may trigger harmful protein changes in the brain that lead to neurodegeneration.

    Lewy body diseases are a group of neurodegenerative disorders marked by the abnormal buildup of a protein, alpha-synuclein, in the brain. These clumps, known as Lewy bodies, are a hallmark of the conditions Parkinson’s disease and Lewy body dementia.

    The study, published in Science September 4, builds on a decade of research linking exposure to fine particulate air pollution (PM2.5) — tiny particles from industrial activity, residential burning, wildfires and vehicle exhaust — to a higher risk of developing these diseases, says lead investigator Xiaobo Mao, Ph.D., associate professor of neurology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Institute for Cell Engineering.

    In their new work, Mao’s team discovered that exposing mice to PM2.5 triggered the formation of abnormal alpha-synuclein clumps. These toxic protein clusters shared key structural and disease-related features with those found in the brains of patients with Lewy body dementia.

    “We have identified a novel strain of Lewy bodies formed after exposure to air pollution,” Mao says. “By defining this strain, we hope to establish a specific target for future drugs aimed at slowing the progression of neurodegenerative diseases marked by Lewy bodies.”

    The research began with an analysis of hospital data from 56.5 million U.S. patients admitted between 2000 and 2014 with neurodegenerative diseases. The team focused on patients hospitalized for the first time with Lewy body-related conditions and used data from their ZIP codes to estimate their long-term exposure to PM2.5. The scientists found that each interquartile range increase in PM2.5 concentration in these ZIP code areas resulted in a 17% higher risk of Parkinson’s disease dementia and a 12% higher risk of dementia with Lewy bodies.

    “The statistical association we uncovered is even stronger than what previous studies found when lumping all Alzheimer’s and related dementias together — highlighting Lewy body formation as a potentially pivotal pathway that warrants deeper biological investigation,” says Xiao Wu, Ph.D., a co-first and co-corresponding author of the study and assistant professor of biostatistics at Columbia University Mailman School of Public Health. “We hope to inspire researchers to conduct both epidemiologic and molecular studies that focus on dementia subtypes linked to Lewy bodies.”

    Exploring the biological reason for this association between exposure to PM2.5 and Lewy body dementia, Mao’s team of researchers exposed both normal mice and genetically modified mice lacking the alpha-synuclein protein to PM2.5 pollution every other day for a period of 10 months.

    “In normal mice, we saw brain atrophy, cell death and cognitive decline — symptoms similar to those in Lewy body dementia,” says study collaborator Ted Dawson, M.D., Ph.D., the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and director of the Institute for Cell Engineering. “But in mice lacking alpha-synuclein, the brain didn’t exhibit any significant changes.”

    The researchers then studied mice with a human gene mutation (hA53T) linked to early-onset Parkinson’s disease. After five months of PM2.5 exposure, these mice developed widespread pockets of alpha-synuclein and experienced cognitive decline. Observed through biophysical and biochemical analysis, these protein clumps were structurally distinct from those that form during natural aging.

    The researchers also set out to determine whether air pollution effects varied by location. They found that mice exposed to separate samples of PM2.5 from China, Europe and the United States led to similar brain changes and development of alpha-synuclein pockets.

    “This suggests that the harmful effects of PM2.5 may be broadly consistent across different regions,” says Haiqing Liu, Ph.D., first author of the study and postdoctoral fellow at Johns Hopkins University School of Medicine.

    The researchers say changes in gene expression in the brains of PM2.5-exposed mice were strikingly similar to those found in human patients with Lewy body dementia.

    “This suggests that pollution may not only trigger the build-up of toxic proteins but also drive disease-related gene expression changes in the human brain,” says Shizhong Han, Ph.D., lead investigator at the Lieber Institute and for Brain Development and an associate professor of psychiatry and behavioral sciences at the school of medicine.

    “We believe we’ve identified a core molecular link between PM2.5 exposure and the propagation of Lewy body dementia,” Mao says.

    While genetic factors play a significant role in neurodegenerative disease, the researchers say people can potentially control their exposure to pollution.

    “Our next goal is to figure out which specific components in air pollution are driving these effects,” says Xiaodi Zhang, Ph.D., a first author of the study and postdoctoral fellow at the school of medicine. “Understanding that could help guide public health efforts to reduce harmful exposures and lower the risk of disease.”

    Reference: Zhang X, Liu H, Wu X, et al. Lewy body dementia promotion by air pollutants. Science. 2025;389(6764):eadu4132. doi: 10.1126/science.adu4132

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    Continue Reading

  • News: CMN Weekly (5 September 2025) – Your Weekly CRISPR Medicine News – CRISPR Medicine News

    News: CMN Weekly (5 September 2025) – Your Weekly CRISPR Medicine News – CRISPR Medicine News

    1. News: CMN Weekly (5 September 2025) – Your Weekly CRISPR Medicine News  CRISPR Medicine News
    2. CRISPR’s Efficiency Triples With Spherical Nucleic Acid Delivery System  Northwestern University
    3. Flashpoint Therapeutics Announces Major Publication Supporting Application of its Proprietary Structural Nanomedicine Platform to CRISPR-based Therapeutics  Yahoo Finance
    4. New nanostructure makes CRISPR edits safer and three times faster  Drug Target Review

    Continue Reading

  • Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation

    Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation

    A randomized controlled trial investigating the effect of providing personalized risk information to patients and their providers about the patient’s risk for advanced colorectal neoplasia has found no difference in screening uptake with either the personalized risk messages or provider notifications. However, the personalized risk messages did increase uptake of stool testing in one health-care system. The study by Schwartz et al was published in Annals of Internal Medicine.

    Study Methodology

    The researchers analyzed data from 214 providers and 1,084 patients at average risk for colorectal cancer across 41 primary care clinics in two health-care systems in the Midwest between November 2020 and May 2023. Eligible patients were aged 50 to 75 years who were scheduled to see a provider within a month and were due for a colorectal cancer screening.

    Study participants were randomly assigned to view a colorectal screening decision aid with or without a personalized message (personalized decision aid or generic decision aid, respectively) about their advanced colorectal neoplasia risk. Providers were randomly assigned to receive notifications that their patient was due for screening, with or without a personalized message about the patient’s advanced colorectal neoplasia risk (personalized notification or generic notification, respectively).

    The primary outcome was completion of any screening test within 6 months of enrollment. Secondary outcomes were completion of each specific screening test—including colonoscopy, stool test, and other approved screening tests—within 6 months. Logistic regression was used to estimate intervention effects.

    Results

    The researchers found that overall, there were no differences in screening uptake or test completion for the provider notification (predicted probabilities = 41.5% vs 36.4% for personalized vs generic; difference = 5.1 [95% confidence interval (CI) = –1.6 to 11.8] percentage points) or decision aid (predicted probabilities = 36.8% vs 41.0% for personalized vs generic; difference = –4.1 [95% CI = –10.2 to 1.9] percentage points) interventions.

    Health system was an effect moderator for stool testing. For one health-care system, the stool testing rate was higher for personalized vs generic provider notification (predicted probabilities = 21.1% vs 7.9%; difference = 13.2 [95% CI = 1.6–24.8] percentage points) when the decision aid was generic.

    The stool testing rate was higher for the personalized vs the generic decision aid (predicted probabilities = 21.4% vs 7.9%; difference = 13.5 [95% CI = 2.4–24.5] percentage points) when the provider notification was generic.

    “Although including personalized risk for ACN [advanced colorectal neoplasia] in a decision aid or provider notification had no overall effect, it increased uptake of stool testing in one health system. …These findings require confirmation and extension in subsequent studies with potential to improve the uptake, effectiveness, and efficiency of colorectal cancer screening,” concluded the study authors.

    Peter H. Schwartz, MD, PhD, lead author of this study and Director of the Indiana University Center for Bioethics at Indiana University School of Medicine, is the corresponding author of this study.

    Disclosure: Funding for this study was provided by the Patient-Centered Outcomes Research Institute. For the study authors’ conflict-of-interest disclosures, visit www.acpjournals.org/journal/aim.

    Continue Reading

  • Modified Glue Gun Delivers Personalized Fracture Treatment – Inside Precision Medicine

    1. Modified Glue Gun Delivers Personalized Fracture Treatment  Inside Precision Medicine
    2. A modified hot glue gun can mend broken bones  New Scientist
    3. Scientists develop ‘glue gun’ that 3D prints bone grafts directly onto fractures  Live Science
    4. 3D printing ‘glue gun’ can generate bone grafts directly onto fractures  Medical Xpress

    Continue Reading

  • New MRI correction method reveals brain structure differences in children with ADHD

    New MRI correction method reveals brain structure differences in children with ADHD

    Over five percent of children and adolescents are diagnosed with attention deficit/hyperactivity disorder (ADHD) globally. This condition is characterized by a short attention span, hyperactivity or impulsive behavior that is age-inappropriate, making it difficult for patients to navigate interpersonal relationships, the formal education system, and social life. Researchers have used brain imaging analyses such as magnetic resonance imaging (MRI) to understand the neurological basis of ADHD. Understanding brain structure abnormalities that lead to ADHD-related pathologies is crucial for designing early assessment and intervention systems, especially for children.

    Although multiple studies have used MRI to understand ADHD in children, the results have been inconclusive. While some brain imaging studies have shown decreased gray matter volume (GMV) in children with ADHD, others have either reported no change or an increase in GMV compared to subjects without ADHD. These conflicting results are mostly due to small sample sizes, differences in MRI machines used, or the variation among the subjects recruited. Previous studies have accounted for the bias caused by different MRI machines using a method called ComBat harmonization, which controls for site and MRI differences in large samples. However, ComBat overcorrects sampling bias, which may include biological characteristics of the sample; therefore, it may not be able to accurately correct the MRI differences.

    The traveling-subject (TS) method is a new correction approach to account for variations in measurements across MRI machines for the same subject. In this method, measurement biases can be controlled for the same participants using MRI scans from multiple institutions, facilitating the collection of more accurate datasets. In this collaborative study, Assistant Professor Qiulu Shou and Associate Professor Yoshifumi Mizuno from the University of Fukui, Japan, Professor Yoshiyuki Hirano from Chiba University, Japan, and Professor Kuriko Kagitani-Shimono at The University of Osaka, Japan, validated the TS method in an independent dataset. Their findings were published in Molecular Psychiatry on August 8, 2025.

    Dr. Shou introduces the methodological framework of the study: “MRI data of 14 TS, 178 typically developing (TD) children, and 116 children with ADHD were collected from multiple sites, and the TS method and ComBat were used to correct for measurement bias.” Fourteen healthy subjects underwent MRI scans on four different machines over a three-month period to extract measurement biases across these machines. This was then applied to an independent dataset of children from the Child Developmental MRI (CDM) database. The CDM database was jointly established by the University of Fukui, The University of Osaka, and Chiba University, with the goal of collecting brain imaging data from over 1,000 child participants for research on neurodevelopmental disorders such as ADHD. GMV was then estimated and compared between the two groups of children in the study. The research team calculated measurement and sampling biases among TS-corrected, ComBat-corrected, and raw data. The results showed that compared to raw data, the TS method significantly reduced measurement bias while maintaining sampling bias. In contrast, ComBat effectively reduced measurement bias and significantly decreased sampling bias.

    “TS-corrected data showed decreased brain volumes in the frontotemporal regions in the ADHD group compared to the TD group,” explains Dr. Mizuno while discussing their findings. “Patients with ADHD displayed smaller volumes in those regions of the brain that are crucial for cognitive functions, such as information processing and emotional control, which are often affected in these patients,” adds Dr. Shou.

    Furthermore, if TS-harmonized multi-site MRI data on specific brain structure patterns can be associated with ADHD, they can then be used as neuroimaging biomarkers for accurate and early ADHD diagnosis, treatment, and treatment outcome monitoring, leading to effective personalized therapeutic strategies.

    By applying the TS harmonization method to correct for site-related biases in multi-site MRI data, this study aims to identify brain structure characteristics in children with ADHD. These identified characteristics could facilitate earlier diagnosis and more precise, individualized interventions. In the long term, this approach may improve the quality of life for affected children and reduce the risk of secondary psychiatric disorders,” concludes Dr. Shou.

    Source:

    Journal reference:

    Shou, Q., et al. (2025). Brain structure characteristics in children with attention-deficit/hyperactivity disorder elucidated using traveling-subject harmonization. Molecular Psychiatry. doi.org/10.1038/s41380-025-03142-6

    Continue Reading